This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $226,008 | $316,809 | $162,521 | $621,589 | $519,689 |
| FY2023 | 990 | $772,336 | $966,416 | $735,156 | $712,390 | $610,490 |
| FY2022 | 990 | $418,620 | $308,337 | $166,085 | $906,470 | $804,570 |
| FY2021 | 990 | $544,244 | $386,234 | $241,485 | $796,187 | $694,287 |
| FY2020 | 990 | $708,384 | $537,191 | $474,696 | $638,177 | $536,277 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 58% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| Mulberry TherapeuticsWellesley Hills, MA | research | $521,000 | 2023 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Nicole Henwood | PRESIDENT | 20.00 | $12,800 |
| Gilles Atlan | VICE PRESIDENT | 20.00 | $3,200 |
| Vito Grasso | DIRECTOR | 1.00 | $0 |
| Chris Serle | DIRECTOR |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| therapy for NF2 |
| $394,000 |
| 2020 |
| Mass Gen Development OfficeBoston, MA | development of bacteriotherapy for NF2 | $100,000 | 2021 |
| Yale UniversityNew Haven, CT | tumor imaging model | $72,702 | 2022 |
| Mass Gen Development OfficeBoston, MA | development of bacteriotherapy for NF2 | $60,512 | 2023 |
| RESEARCH INSTITUTE AT NATIONWIDE CHCOLUMBUS, OH | RESEARCH | $60,380 | 2024 |
| MASS GEN DEVELOPMENT OFFICEBOSTON, MA | DEVELOPMENT OF BACTERIOTHERAPY FOR NF2 | $60,000 | 2024 |
| Laboratory of Gary Brenner MDBoston, MA | development of bacteriotherapy for NF2 | $57,500 | 2021 |
| Indiana University ResearchBloomington, IN | research | $47,007 | 2023 |
| Indiana University ResearchBloomington, IN | drug testing | $47,007 | 2021 |
| Institute for Cancer ResearchPhiladelphia, PA | research | $37,500 | 2022 |
| Yale UniversityNew Haven, CT | tumor imaging model | $36,351 | 2023 |
| YALE UNIVERSITYNEW HAVEN, CT | TUMOR IMAGING MODEL | $36,351 | 2024 |
| William Cancer Institute PCBeverly Hills, CA | research | $35,436 | 2023 |
| Merlin TherapeuticsKing Of Prussia, PA | Not available | $30,200 | 2023 |
| CHOP Research InstitutePhiladelphia, PA | developing a tumor biobank for NF2 | $23,724 | 2021 |
| Mass Gen Development OfficeBoston, MA | development of bacteriotherapy for NF2 | $20,000 | 2022 |
| Yale UniversityNew Haven, CT | tumor imaging model | $13,254 | 2021 |
| CHOP Research InstitutePhiladelphia, PA | developing a tumor biobank for NF2 | $7,983 | 2022 |
| MERLIN THERAPEUTICSKING OF PRUSSIA, PA | RESEARCH | $5,791 | 2024 |
| University of CaliforniaLos Angeles, CA | research | $5,000 | 2022 |
| Cell Culture Company LLCMinneapolis, MN | research | $1,838 | 2023 |
| Research Institute at Nationwide ChColumbus, OH | research | $1,000 | 2023 |
| University of CaliforniaLos Angeles, CA | research | $812 | 2023 |
| CHOP Research InstitutePhiladelphia, PA | developing a tumor biobank for NF2 | Not available | 2023 |
| 1.00 |
| $0 |
| Amy Williams | DIRECTOR | 5.00 | $0 |
| Deian Owen | TREASURER | 5.00 | $0 |
| Mary Sell | DIRECTOR | 5.00 | $0 |
| Jill Velez | SECRETARY | 5.00 | $0 |
| Claudia Schmidt | DIRECTOR | 5.00 | $0 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202443149349300734
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202343009349300304
Form 990 · FY2021 · period ending Dec 31, 2021
Filing id 202222309349300337
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202201379349300835
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.